Trevi Therapeutics Announces Upcoming Investor Conferences
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical organization, is paving the way in the biopharmaceutical field with its innovative therapy Haduvio™. This oral nalbuphine extended-release solution uniquely targets chronic cough, particularly in cases involving idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). With significant improvements in patient management on the horizon, Trevi has scheduled several prominent investor conferences in March.
Key Conference Participation
The initial conference on Trevi's agenda is the TD Cowen 45th Annual Health Care Conference, held from March 3-5 in Boston. During this event, key representatives from Trevi will be making a corporate presentation on March 4 from 10:30-11:00 am ET. The team's presentation will be spearheaded by Chief Financial Officer Lisa Delfini and Chief Commercial Officer Farrell Simon, who are looking forward to connecting with investors interested in Trevi's innovative approach.
Following this, Trevi will participate in the Leerink Partners Global Healthcare Conference, taking place from March 10-12 in Miami. On March 12 at 8:00 am ET, President and CEO Jennifer Good, alongside Chief Development Officer James Cassella, will share insights into Trevi's strategic vision and the promising potential of Haduvio.
Further Engagement at the Mountain Meeting
Trevi will also be present at the Leerink Partners Mountain Meeting, happening from March 23-26 in Jackson Hole. This venue will feature a presentation by CFO Lisa Delfini, again emphasizing the company's commitment to investor relations and its drive to advance chronic cough treatments.
Understanding the Impact of Chronic Cough
Chronic cough has been identified as a deeply troubling condition for many patients, particularly those suffering from IPF. Remarkably, it affects up to 85% of individuals with this disease. Patients may find themselves coughing as many as 1,500 times in a single day, leading to a substantial decline in their quality of life. The absence of approved treatments for chronic cough in IPF patients only compounds this crisis, highlighting the urgent need for innovative solutions like Haduvio.
Refractory chronic cough, impacting two to three million adults in the U.S., further amplifies the situation, causing significant complications ranging from sleep disturbances to social issues. It’s a highly disruptive condition that can lead to severe emotional and physical consequences. The current landscape shows no approved treatment for RCC, marking an essential opportunity for Trevi and its development of Haduvio.
About Haduvio and Its Mechanism
Haduvio is poised to become a valuable asset in addressing chronic cough symptoms effectively. It operates on the cough reflex arc and engages both central and peripheral pathways as a kappa agonist and a mu antagonist, which play significant roles in controlling cough hypersensitivity. It's essential to note that nalbuphine, the main component of Haduvio, is not categorized under controlled substances by the U.S. Drug Enforcement Agency, which may simplify its distribution and accessibility when it becomes available for use.
Looking Ahead: Trevi's Commitment to Patients
As Trevi prepares for these conferences, its representatives are enthusiastic about sharing their advancements and gathering support for Haduvio. They emphasize the gravity with which they regard the struggles faced by patients with chronic cough, recognizing the toll it takes on health and well-being.
With the extensive target population and the pressing need for effective treatment options, Trevi's innovative approach may significantly alter the treatment landscape for chronic cough, potentially improving the lives of countless patients.
Frequently Asked Questions
What is Haduvio, and how does it work?
Haduvio is an investigational oral therapy aimed at treating chronic cough by targeting cough reflex pathways. Its mechanism involves acting on specific opioid receptors to control cough hypersensitivity.
When will Trevi Therapeutics present at the investor conferences?
Trevi will present at various conferences throughout March, with notable presentations occurring on March 4 and March 12.
What is the significance of chronic cough in IPF patients?
Chronic cough significantly affects IPF patients, impacting their quality of life. It can lead to extensive daily disruptions and the potential worsening of their condition.
Is there any approved treatment for refractory chronic cough?
Currently, there are no approved therapies for refractory chronic cough in the U.S., highlighting the urgent need for effective solutions like Haduvio.
What role does Trevi Therapeutics play in addressing chronic cough?
Trevi Therapeutics is developing Haduvio to address chronic cough, focusing on improving treatment outcomes for patients suffering from difficult-to-treat conditions.
